Diabetes mellitus (DM) is well-known as a disorder that increases the risk of infectious diseases. Various reports have shown that innate immunity is impaired in patients with DM, which is considered to be a major cause of increased risk of infectious diseases. However, there is a paucity of data about the actual risk of mold infections in patients with DM. Several treatment procedures, such as solid organ transplantation and hematopoietic stem cell transplantation (HSCT), are intrinsically associated with a high risk of mold infections and also correlated with an increased risk of post-transplant DM. Therefore, we could assume that organ transplant recipients or HSCT recipients with DM are at quite high risk of mold infections. Here, we aim to summarize the information about the increased risk of mold infections in patients with DM, and propose possible interventions such as intensive glucose control to reduce this risk in patients with DM.
INTRODUCTION
Diabetes mellitus (DM) is well-known as a disorder that increases the risk of infectious diseases. 1, 2 It is reported that innate immunity is impaired in patients with DM. 1, 3, 4 However, there is a paucity of data about the risk of mold infections in patients with DM because the incidence is rather low, although it seems to be significantly higher than that in general population. Several treatment procedures, such as solid organ transplantation and hematopoietic stem cell transplantation (HSCT), are intrinsically associated with a high risk of mold infections and also correlated with an increased risk of post-transplant DM. 5 The mechanism whereby the presence of DM affects the incidence of mold infections in such cases is intriguing. Here, we aim to summarize the information about the increased risk of mold infections in patients with DM, and propose possible interventions to reduce this risk.
PATHOPHYSIOLOGY
In healthy individuals, innate immunity is sufficiently effective to prevent mold infections, [6] [7] [8] and has an important role in their control. 9 Recent findings also suggest the importance of adaptive immunity such as Th1 cells, which was reviewed elsewhere. 10 The significantly increased risk of fungal infections in patients with chronic granulomatous disease, which is genetically associated with defective phagocyte function, supports the importance of phagocytes in the control of mold infections. [11] [12] [13] There are several causes of insufficient protection by neutrophils, as summarized in Table 1 . Prevention of aspergillosis and mucormycosis require control of either spore germination or hyphal growth by host immune defenses. In healthy immunocompetent people, PMNs and macrophages/monocytes phagocytose spores and inhibit spore germination and hyphal growth. DM impairs the functionality of innate immunity through various mechanisms.
14 McManus et al. 15 reported that an agonist-selective reduction in in vitro responsiveness of PMNs was inversely correlated with glucose control in vivo. Stegenga et al. 16 found that even short-duration hyperglycemia (8 h) significantly reduced neutrophil degranulation and exaggerated coagulation in the innate immune response against endotoxin. Hyperglycemia was also shown to inhibit chemokinesis in normal human neutrophils. 17 Although insulin can stimulate neutrophil chemokinesis, hyperglycemia inhibits the insulin receptor signal transduction cascade.
Using animal models, various studies showed that hyperglycemia was associated with impairment of neutrophil function. Rats with alloxan-induced diabetes demonstrated impaired phagocytosis of Candida albicans and reduced neutrophil myeloperoxidase activity. 18 Hyperglycemia was shown to impair the chemotaxis of neutrophils in a mouse model of chronic hyperglycemia. 19 Yano et al. 20 found that diabetic model mice, including db/db and high-fat-diet mice, exhibited signs of neutrophil dysfunction such as decreased phagocytosis, superoxide production and killing activity of Staphylococcus aureus, and insulin treatment restored these functions. In terms of mold infections, the presence of DM increased the risk of Aspergillus and Mucor infections in animal models, [21] [22] [23] although the susceptibility to Aspergillus was intriguingly far lower than that to Mucor. 22 Although it is not yet clear why the susceptibility to mucormycosis in patients with DM is higher than that to aspergillosis, the impairment of innate immunity may have a number of causes, as discussed above. 15 In summary, hyperglycemia was shown to impair the function of neutrophils in animal models and humans.
In addition, high-dose systemic steroids, commonly used as immunosuppressants were reported to be a risk factor for mold infections when used for the treatment or prophylaxis of GvHD. [24] [25] [26] [27] Corticosteroids significantly impair the functionality of innate immunity. 21, 23 In normal subjects, generation of reactive oxygen species by PMNs or mononuclear cells was inhibited by hydrocortisone at 1 h, with a peak at 2 h; recovery began at 4 h but lasted up to 8 h. 28 The effects were mediated by an increase of IκB suppressing NFκB. 29 Steroid-induced hyperglycemia, a problem at high steroid doses, might further weaken the innate immune response against mold infections. Therefore, we assume that in patients with hyperglycemia associated with high-dose corticosteroids, we should pay significant attention to mold infections as both high-dose corticosteroids and hyperglycemia cause neutrophil dysfunction.
EPIDEMIOLOGY OF MOLD INFECTIONS
Invasive mold infections are associated with high mortality. [30] [31] [32] [33] Thus, prevention is an important strategy to be applied to patients at high risk of invasive mold infections. Optimization of prevention strategies requires a useful risk stratification system. Host factors are important to identify patients who are at high risk for invasive fungal infection (IFI). The European Organization for the Research and Treatment of Cancer/Mycoses Study Group criteria describe five host factors that do not include hyperglycemia/DM: prolonged neutropenia, allogeneic HSCT, prolonged use of corticosteroids, receipt of T-cell immunosuppressants and inherited immune deficiency. 34 Mold infections in patients with DM We first aim to give an overview of previous reports relating to mold infections and DM in the general population, although a small proportion of patients in these studies received HSCT or other treatments. In terms of Aspergillus infection, DM has not been recognized as a risk factor for invasive aspergillosis in the general population. However, in the reports of Aspergillus infections, the proportion of patients with DM tended to be high. For instance, Nivoix et al. 35 reported that 53 out of 289 patients (18.3%) with invasive aspergillosis had DM. Therefore, larger studies are needed to correctly assess the impact of DM on the risk of invasive aspergillosis. In terms of Mucor infection, previous reports using registries of Mucor infections showed that a significant proportion of patients with proven or probable Mucor infections had DM. 32, [36] [37] [38] In proven cases of mucormycosis the fatality rate was reported to be high, even in patients with DM as the sole underlying condition. [36] [37] [38] Roden et al. 38 established a database consisting of 929 cases in 459 published reports from 1885 to 2004. In their study, the underlying condition at the time of infection was DM in 337 patients (36.3%) and bone marrow transplantation in 44 patients (4.7%). 38 Out of the 337 patients with DM as an underlying condition, only 68 (20%) had type 1 diabetes, and of these, only 33 (48%) had documented ketoacidosis. Conversely, most patients with DM had type 2 diabetes (n = 187), with 64 patients (34%) having documented ketoacidosis. Therefore, only one-third of DM patients had ketoacidosis at the diagnosis of mucormycosis infection, which suggested that ketoacidosis is not a prerequisite for Mucor infections. Sinus involvement constituted the majority of infections (222 (66%) out of 337) in patients with DM, which contrasted with the finding that in patients with malignancy and recipients of bone marrow transplants, over half of infections occurred in the lungs. Rüping et al. 37 38, 39 DM was reported in 37 (22%) patients, more than half of whom (21 patients, 12%) had another risk factor in addition to DM. Taken together, 37% of the 169 total cases received prolonged steroid therapy. 39 As the findings of this study demonstrate, DM seems to be a risk factor for mold infections, in particular Mucor infections. However, due to the fact that the database included only patients who developed mold infections, it is impossible to assume that DM causes an absolute increase in the risk of mold infections.
Mold infections in patients with DM and a coexisting predisposing disorder It is also important to clarify the impact of DM in patients with another predisposing condition such as solid organ transplantation, hematological malignancy with chemotherapy or HSCT, as the combination could significantly increase the risk of mold infections and could therefore alter the appropriate intensity of fungal infection prophylaxis. However, the impact of pretransplant DM on the incidence of mold infection is still rather undetermined. Pre-transplant DM is not included as a host factor predisposing individuals to IFIs, 34 and is often not taken into account even in large studies focusing on IFIs after solid organ transplant or allogeneic HSCT. 34, 40, 41 In terms of Mucor infection, the incidence itself is rather low. 42 Therefore, a large database is needed to assess the impact of DM. Here, we summarize the reports relating to mold infections and DM.
Several studies reported the association between the presence of DM and IFIs in patients with another predisposing condition. The reports relating to organ transplantation or allogeneic HSCT are summarized in Table 2 . Sahin et al. 43 identified the presence of DM as an independent risk factor (odds ratio (OR) 6.01, 95% confidence interval (CI) 2.95-12.25, P o 0.01), while both Tharayil John et al. 44 and Altiparmak et al. 45 identified post-transplant DM as a predisposing factor, the former in a multivariate analysis (hazard ratio (HR) 2.07, 95%CI 1.20-3.55, P = 0.0086). Abbott et al. 46 analyzed 33 420 renal transplant recipients in the United States Renal Data System in a retrospective study of fungal infection during hospitalization. In this study, 125 out of 288 patients (45%) with fungal infection had pre-transplant DM, and pre-transplant 47 studied the incidence of fungal infection after allogeneic HSCT from 1998 to 2002 in Seattle. The presence of hyperglycemia was a risk factor for early invasive mold infection (days 1-39 after allogeneic HSCT; HR 4.2, 95%CI 2.0-8.7, P o0.001). Liu et al. 48 retrospectively analyzed the incidence and risk factors for proven or probable IFI in adult allogeneic HSCT recipients. Nineteen out of 421 patients (4.5%) had pre-transplant DM, and pre-transplant DM was a risk factor for IFI in univariate analysis (HR 3.49, 95%CI 1.05-11.65, P = 0.042), although it was not significant in multivariate analysis. Significant post-transplant risk factors for IFI were grade III-IV acute GvHD and high-dose steroid therapy. Caira et al. 49 reported the results of the SEIFEM 2010-a multicenter study that assessed several pre-chemotherapy risk factors for IFIs in 881 patients who received intensive chemotherapy for newly diagnosed acute myeloid leukemia. DM was present in nine patients (17%) with mold infections but only 43 patients (6.5%) without mold infections, and we can calculate that the presence of DM was a risk factor for mold infections in a univariate analysis (OR 2.90, 95% CI 1.17-6.52, P = 0.01).
Further studies focused on the characteristics of patients who developed Mucor infection. Kontoyiannis et al. 50 reported the characteristics and clinical outcomes of patients with mucormycosis, in comparison with patients with invasive aspergillosis or those without fungal infection. Among 27 cases with Mucor infection, nearly all had a hematological malignancy; further, 13 (48.1%) received allogeneic HSCT, 19 (70.4%) received corticosteroid therapy, 10 (37%) had history of DM and seven (25.6%) had glucose levels 4200 mg/dL at the diagnosis of Mucor infection. In multivariate analysis, a history of DM (OR 8.39, 95%CI 2.04-34.35, P = 0.003), malnutrition defined as albumin level o3.0 g/dL (OR 3.7, 95%CI 1.03-13.27, P = 0.045), and voriconazole prophylaxis (OR 10.37, 95%CI 2.76-38.97, P = 0.001) were significant risk factors for mucormycosis. Singh et al. 51 reported the results of a matched case-controlled study in solid organ transplant recipients. underlying disease; survival was lower in the malignancy group. Therefore, we would expect that patents with both a hematological malignancy and DM had an inferior outcome relative to patients with ⩾ 2 underlying conditions (HR 5.9, 95%CI 1. 54 reported 105 cases of mucormycosis after solid organ transplantation (n = 28) or HSCT (n = 77). Active diabetes at the time of infection, either corticosteroid-associated or as a preexisting condition, was present in 46 (43.8%) patients with mucormycosis. The overall cumulative incidence of mucormycosis at 1 year was 0.29%. The cumulative incidences of mucormycosis at 1 year were 0.85% after unrelated HSCT, 0.58% after HLA-matched related HSCT, and 0.25% after HLA-mismatched related HSCT. Our group also reported that the risk of infection-related mortality in patients with pre-transplant DM was significantly higher than that in patients without pretransplant DM, especially the risk of fungus-related mortality. 55 Although there was no statistically significant difference in the incidence of Aspergillus and Candida infections, the risk of Mucor infections was significantly higher in patients with pre-transplant DM, although the incidence itself was low (HR 9.91, 95%CI 2.99-32.88, P o 0.01). Davoudi et al. 56 also found that in adult hematological malignancy patients with proven or probable invasive mold sinusitis, patients with Mucor infections were more likely to have a history of DM.
In terms of fusariosis, data is limited compared with Aspergillus and Mucor infections. A previous study performed a literature search and found that 17 out of 27 cases with fusariosis had DM. 57 A recent large study from Brazil reported that the presence of hyperglycemia was a significant risk factor for invasive fusariosis after allogeneic HSCT (HR 5.17, 95%CI, 1.40-19.11). 58 In terms of other rare mold infections such as those caused by the so called 'black molds' (for example, Stachybotrys), it is difficult to assess the impact of hyperglycemia due to the rarity of such diseases.
In summary, various clinical studies found that the presence of DM before solid organ transplantation, chemotherapy or allogeneic HSCT seemed to be associated with an increased risk of mold infections, in particular Mucor infections.
POSSIBLE IMPLICATIONS OF GLUCOSE CONTROL TO REDUCE THE RISK OF MOLD INFECTIONS
As described above, various studies in both animals and humans showed that uncontrolled hyperglycemia increased the risk of mold infection. Therefore, it is reasonable to assume that improved glucose control might reduce the risk of mold infection after allogeneic HSCT. Patients often have hyperglycemia after allogeneic HSCT, as reviewed recently. 5, 59 Considering the importance of neutrophil function in the control of bacterial infections, we can assume that better glucose control might reduce the risks of both bacterial and fungal infections. In particular, glucose control after allogeneic HSCT during the early neutropenic period could be crucial, as the risk of bacterial and fungal infections is high due to profound neutropenia, and the risk of developing hyperglycemia is also high due to various causes such as inflammation associated with conditioning regimens and total parenteral nutrition. 60, 61 The development of infectious diseases during the early post-transplant period might lead to an increased risk of subsequent complications. 62, 63 In a small prospective study designed to assess the feasibility and effectiveness of intensive glycemic control (IGC) after allogeneic HSCT, there were significantly fewer documented infections in patients undergoing IGC compared with the matched-control group, although the study population was too small to assess the impact of IGC on the incidence of mold infections. 64 Although a multicenter clinical trial incorporating IGC for patients treated with allogeneic HSCT using myeloablative conditioning regimens is ongoing in Japan (UMIN000001189), it is also too small to assess the impact of IGC on the incidence of mold infections. A larger confirmatory study is needed to determine the benefits of IGC in patients at very high risk of mold infections (Figure 1) .
Although there is no firm evidence of IGC, as reviewed previously, 5 glucose control is recommended not only during the early period after allo-HSCT but also at long-term follow-up. It is also important to treat DM before allo-HSCT to improve the glucose control after allo-HSCT. 59 To achieve the sufficient and safe glucose control, close collaboration between hematologists and endocrinologists is mandatory.
CONCLUSION
Both animal and human studies clearly showed that hyperglycemia impairs innate immunity. Patients with hyperglycemia exhibit signs of neutrophil dysfunction, such as decreased phagocytosis, superoxide production and killing activity, which must consequently increase the risk of mold infections. The clinical benefits of IGC in patients who are at high risk of mold infections should be determined by prospective studies.
